Find Funding Opportunities

Request Information RFI): Opportunities Advance Clinical Epidemiologic Research Facilitate Aging Place utilizing In-Home Monitoring Notice Number: NOT-HL-14-222 Update: following update relating this announcement been issued: April 29, 2014 - Notice to inform potential participants the National Institute Neurological Disorders Stroke NINDS) participate NOT-HL-14-222. Notice NOT-NS-14-029. Key Dates Release Date: April 24, 2014 Response Date: June 25, 2014 Related Announcements None Issued National Heart, Lung, Blood Institute NHLBI) National Cancer Institute NCI) National Institute Aging NIA) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Disability Rehabilitation Research NIDRR) National Institute Neurological Disorders Stroke NINDS) Office Behavioral Social Sciences Research OBSSR) Administration Community Living ACL) Office Women's Health OWH) U.S. Department Veterans Affairs VA) Purpose Request Information RFI) seeks input opportunities, appropriate infrastructure, critical needs key questions will advance research order optimize care treatment, independence community living the aging population individuals chronic disabilities e.g., physical, developmental, and/or intellectual disabilities) aimed supporting aging place reducing hospitalization admissions a nursing facility. NHLBI invites comments researchers, patient advocacy groups, patients, device companies, healthcare providers. Background understanding the current status future directions Aging Systems Technology AST) aging, chronic disabilities, community living independence needed order examine critical gaps knowledge, standards, infrastructure supports.  potential and benefits these technologies of great interest since population aging people living longer multiple chronic conditions. background information be found the following link: http://aspe.hhs.gov/daltcp/reports/2012/astsrptcong.shtml Information Requested RFI intended solicit perspectives comments the broad community scientific opportunities, critical needs optimal configurations conducting research the area unobtrusive in-home monitoring the aging population individuals chronic disabilities.  comments include are limited to: 1.  most important questions challenges over next 5-10 years regarding technology facilitate independent aging. 2. Programs, investments, and/or grant mechanisms NIH ought consider order foster clinical epidemiologic research the of in-home monitoring devices, including tele-health, assist elderly individuals chronic disabilities remain home. 3. Recommendations programs, infrastructure investments best address important questions this field focused research questions. 4. Optimal configurations allowing innovation autonomy private companies interact academic research provide information improving health care reducing transitions care facilities. 5.  Scale-up evaluations deployment technology transfer considerations validation algorithms sensed data home healthcare uses. you choose to identify yourself replying, please identify role the field help us better understand thoughts particular groups.  example, please indicate you a care provider, patient, patient advocate, researcher, device company, etc. Responses ensure consideration, responses should submitted June 25, 2014. Respond email to: iturriae@mail.nih.gov.  Please include text RFI Reply” your subject line. RFI for planning purposes only should be construed a solicitation as obligation the part the Federal Government generally the NIH specifically.  NIH does intend make any awards based responses this RFI to otherwise pay the preparation any information submitted for Government's of such information NIH use information submitted response this RFI its discretion will provide comments any responder's submission.  However, responses the RFI be reflected future solicitation(s).  information provided be analyzed may appear reports.  Respondents advised the Government under obligation acknowledge receipt the information received provide feedback respondents respect any information submitted.  proprietary, classified, confidential, sensitive information should included your response.  Government reserves right use any non-proprietary technical information any resultant solicitation(s). Inquiries Please direct inquiries to: Erin Iturriaga National Heart, Lung, Blood Institute NHLBI) Telephone: 301-435-0403 Email: iturriae@mail.nih.gov  

NINDS Anticipates Holding Future Meetings among PDs/PIs NINDS-Funded Institutional Training T32) Programs Notice Number: NOT-NS-14-026 Key Dates Release Date: April 18, 2014 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose NINDS supports institutional training programs T32s) both predoctoral postdoctoral fellows are intended develop strong next generation neuroscientists engaged research NINDS-mission relevant research-associated occupations. programs expected facilitate development a highly qualified, diverse workforce. purpose this Notice to inform awardees NINDS T32 training programs it anticipates holding meetings among PDs/PIs these programs order coordinate efforts maximize success all programs. offset costs associated attendance these meetings, NINDS provide to 600 direct cost directly the T32 grants, grant PDs/PIs, their designees, attend meetings. meetings scheduled, Director, NINDS Office Training, Career Development Workforce Diversity notify PDs/PIs additional information, including directions requesting funds. Inquiries Please direct inquiries to: Stephen Korn, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-4188 Email: korns@ninds.nih.gov nbsp;

Request Information: Current Clinical Questions Post Resuscitation Hypothermia Notice Number: NOT-GM-14-112 Key Dates Release Date: April 18, 2014 Response Date: 30, 2014 Related Announcements None Issued National Heart, Lung, Blood Institute NHLBI) National Institute General Medical Sciences NIGMS) National Institute Neurological Disorders Stroke NINDS) Purpose Office Emergency Care Research OECR), located within National Institute General Medical Sciences, responsible coordinating fostering NIH support clinical translational research research training the emergency setting.  National Heart, Lung, Blood Institute National Institute Neurological Disorders Stroke the Office Emergency Care Research seek comments regarding clinical research questions surrounding post-resuscitation hypothermia. Request Information RFI) help assist staff promote studies will provide answers the most pressing questions raised clinicians researchers. Background Post cardiac arrest hypothermia shown improve neurological outcomes two studies performed Australia Europe reported 2002 NEJM 2002, 346:549-563 NEJM 2002, 346:557-563). 2010 American Heart Association Guidelines recommend therapeutic hypothermia used comatose adults a pulse following of hospital cardiac arrest Circulation 2010;122: Suppl 3:S768-S786), a 2012 Cochrane review concluded mild therapeutic hypothermia improves survival neurologic outcome after cardiac arrest Cochrane Database Systematic Reviews 2012, Issue 9). recently, studies questioned both timing level hypothermia JAMA. 2014;311(1):45-52 NEJM 2013;369:2197-206), questions appear remain to whether hypothermia more beneficial strict maintenance normothermia.  Information Requested RFI solicits feedback the scientific research communities other interested organizations, the clinical research questions need be answered surrounding post resuscitation therapeutic hypothermia.  Comments include are limited the following areas concern: most pressing scientific questions the utility hypothermia after cardiac arrest. Ethical issues surrounding clinical trial studies strict normothermia vs. hypothermia, any. Features temperature management post arrest patients are most critical study next, i.e., optimal temperature, optimal duration, hypothermia vs. normothermia well any factors are important study. Confinement the patients the next stage hypothermia studies without hospital VF arrest. Methods controlling temperature should used next stage studies temperature management after cardiac arrest; i.e. surface cooling, intravascular cooling, neurological cooling, accompanying medications, etc. study endpoints should/could used. Evaluation re-warming strategies, applicable. to Submit Response Responses the RFI be accepted until 30, 2014.  will receive individualized feedback any suggestions.  basis claims against United States government shall arise a result a response this request information from Unites States government’s of such information. comments must submitted via email text as attached electronic document.  Microsoft documents preferred.  Please submit response to: Jeremy Brown MD Office Emergency Care Research Telephone: 301-594-2755 Email: jeremy.brown@nih.gov Response this RFI voluntary. interested parties invited respond. Any personal identifiers e.g. names, addresses, email addresses,) be removed responses compiled. Only de-identified comments be used. Proprietary, classified, confidential, sensitive information should be included your response. United States government reserves right use any non-proprietary technical information any resultant solicitation(s). RFI for information planning purposes only should be construed a solicitation as obligation the part the United States government provide support any ideas identified response it.  Please note the United States government not pay the preparation any information submitted for use that information.  Responses be compiled shared internally staff the NHLBI, NINDS OECR, with scientific working groups convened these bodies appropriate.  all cases where responses shared, names the respondents be withheld. Inquiries Please direct inquiries to: Jeremy Brown MD Office Emergency Care Research National Institute General Medical Sciences NIGMS) Telephone: 301-594-2755 Email: jeremy.brown@nih.gov nbsp;

Request Information RFI): Impact DSM-5 Changes Diagnostic Criteria Autism Spectrum Disorders ASD) Research Services Notice Number: NOT-HD-14-012 Key Dates Release Date: April 14, 2014 Response Date: 12, 2014 Related Announcements None Issued Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Environmental Health Sciences NIEHS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) Purpose purpose this request information to seek input the scientific community, health professionals, self-advocates patient advocates the research implications recent changes the Diagnostic Statistical Manual Mental Disorders, Fifth Edition DSM-5) diagnostic criteria Autism Spectrum Disorders ASD). Background the publication DSM-5 May 2013, American Psychiatric Association’s official diagnostic criteria ASD changed reflect current scientific knowledge attempt refine criteria reflect wide range symptom expression within diagnostic category.  Specifically, category Pervasive Developmental Disorder PDD), had in since DSM-III published 1980, removed along its subtypes Autistic Disorder, Asperger Disorder, Childhood Disintegrative Disorder, Pervasive Developmental Disorder, Otherwise Specified).  DSM-5 describes category, Autism Spectrum Disorder ASD), specific criteria related deficits social communication/interaction, restricted and/or repetitive patterns behavior.  is metric describing severity specifying accompanying developmental medical conditions. Subsequent the publication the DSM-5, federal Interagency Autism Coordinating Committee IACC) released ldquo;Statement the Interagency Autism Coordinating Committee Regarding Scientific, Practice Policy Implications Changes the Diagnostic Criteria Autism Spectrum Disorder DSM-5)”.  IACC a federal advisory committee, composed federal public members, coordinates ASD-related activities within United States Federal Government.  committee identified several ways which change diagnostic criteria might affect access diagnostic, treatment, other services.  statement identifies several research questions related the implementation the new ASD criteria, including reliability validity the criteria severity ratings, evaluation whether individuals see change their diagnosis, whether is need new revised screening diagnostic tools processes, potential implications the ASD community support access services. National Institutes Health NIH) invested significantly ($192 million fiscal year 2012) biomedical, treatment services research related ASD.  an effort further align research priorities the needs individuals ASD their families, NIH soliciting further input the implications changes ASD diagnostic criteria autism research, well input the potential research inform concerns questions related clinical practice policy. Information Requested NIH requesting additional input the scientific community, health professionals, self-advocates patient advocates the research implications recent changes the Diagnostic Statistical Manual Mental Disorders, Fifth Edition DSM-5) diagnostic criteria Autism Spectrum Disorders ASD).   NIH invites specific detailed input regarding, not limited to, topics below: to address direct implications changes DSM-5 criteria ASD research methodology, including participant selection characterization, measurement tools, data analysis, interpretation results.  Specific methods which questions concerns the impact these changes be resolved within context research investigations/studies. Specific research questions methodologies could inform questions concerns the impact changes DSM-5 criteria ASD clinical practice policy. Responses Responses this RFI voluntary.  Results be shared internally scientific working groups convened NIH, appropriate.  Proprietary, classified, confidential, sensitive information should be included your response.  Government reserves right use any non-proprietary technical information summaries the state the science any resultant solicitation(s).  NIH use information gathered develop grant, contract, other funding priorities initiatives. RFI for information planning purposes only should be construed a solicitation as obligation the part the Federal Government, National Institutes Health NIH), individual NIH Institutes Centers.  NIH does intend make any awards based responses this RFI pay the preparation any information submitted for Government’s of such information. Responses be accepted through 12, 2014.  Electronic responses should addressed DSM-5@mail.nih.gov .  Please include Notice number NOT-HD-14-012 the subject line.   Inquiries Please direct inquiries to: Sujata Bardhan, PhD Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) Email: DSM-5@mail.nih.gov

Notice Intent Publish Funding Opportunity Announcement the Blueprint Neurotherapeutics Network BPN): Small Molecule Drug Discovery Development Disorders the Nervous System UH2/UH3)" Notice Number: NOT-NS-14-020 Key Dates Release Date: Release Date:   April 9, 2014 Estimated Publication Date Announcement: July 2014 First Estimated Application Due Date: October 2014 Earliest Estimated Award Date: July 2015 Earliest Estimated Start Date: July 2015 Related Announcements NOT-NS-14-021 Issued National Institute Neurological Disorders Stroke NINDS) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Dental Craniofacial Research NIDCR) National Institute Drug Abuse NIDA) National Institute Mental Health NIMH) National Center Complementary Alternative Medicine NCCAM) Purpose NIH announces intention publish Funding Opportunity Announcement FOA) investigators seeking support the Blueprint Neurotherapeutics BPN) Network.  Applicants be encouraged utilize customized set contract resources, consultants the BPN Network help advance neuroscience-focused drug discovery development projects the clinic. Notice provided allow potential applicants sufficient time develop meaningful collaborations responsive projects.  Details the planned FOA provided below. Research Initiative Details facilitate drug discovery development the neuroscience community, NIH Blueprint Neuroscience Research http://neuroscienceblueprint.nih.gov/) established Blueprint Neurotherapeutics BPN) Network, collection contract service providers consultants extensive industry experience the areas pharmacology, medicinal chemistry, pharmacokinetics, toxicology, GMP synthesis, formulation development, Phase clinical safety testing. list consultants contract service providers be viewed http://neuroscienceblueprint.nih.gov/bpdrugs/bpn.htm. planned Funding Opportunity Announcement FOA) solicit applications investigators seeking funding through UH2/UH3 phased cooperative agreement mechanism help advance drug discovery development projects the clinic.  Applicants be encouraged build customized utilization BPN services their applications. be eligible the BPN, applicant must well-validated bioactive compound(s) hand; BPN does support screening hit compounds. Projects enter BPN during Discovery Development may seek support through phase I/first-in-human testing. Discovery involves iterative medicinal chemistry improve potency ADMET properties compounds, toward goal identifying clinical candidate. During Development, clinical candidate undergoes preclinical toxicology testing required an IND manufacturing, ultimately advancing phase I/first-in-human testing. BPN Development activities include chemical manufacturing controls CMC), formulation development, toxicology studies, regulatory support, phase I/first-in-human testing. NIH assemble customized Lead Development Team each project accepted the program. Lead Development Team typically be co-chaired the Program Director/Principal Investigator PD/PI) a consultant extensive industry expertise identified supported the NIH. Lead Development Team also include members the PD/PI's team, NIH-hired consultants additional expertise, NIH staff. Lead Development Team plan coordinate work supported the cooperative agreement award conducted BPN contractors. projects enter BPN begin a preparatory phase UH2) up one year, can used complete any studies required meet Discovery Development entry criteria to engage Lead Development Team establishing detailed research plan, go/no-go milestones, all subsequent work. Applicants strongly encouraged consult NIH program staff plans an application being developed. Consultations include conference calls NIH program staff. Early contact provides opportunity NIH program staff discuss program scope, entry criteria, goals, to provide information guidance how develop competitive application. additional information the BPN, please http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: Rebecca Farkas, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779 Email: farkasr@ninds.nih.gov nbsp;

Notice Intent Publish Funding Opportunity Announcement the Blueprint Neurotherapeutics Network BPN): SBIR Small Molecule Drug Discovery Development Disorders the Nervous System U44)" Notice Number: NOT-NS-14-021 Key Dates Release Date: Release Date: April 9, 2014 Estimated Publication Date Announcement: July 2014 First Estimated Application Due Date: October 2014 Earliest Estimated Award Date: July 2015 Earliest Estimated Start Date: July 2015 Related Announcements NOT-NS-14-020 Issued National Institute Neurological Disorders Stroke NINDS) National Institute Alcohol Abuse Alcoholism NIAAA) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Dental Craniofacial Research NIDCR) National Institute Drug Abuse NIDA) National Institute Mental Health NIMH) National Center Complementary Alternative Medicine NCCAM) Purpose NIH announces intention publish Funding Opportunity Announcement FOA) SBIR-eligible small businesses seeking support the Blueprint Neurotherapeutics Network BPN). Applicants encouraged utilize customized set contract resources, consultants the Blueprint Neurotherapeutics Network BPN) help advance neuroscience-focused drug discovery development projects the clinic. Notice provided allow potential applicants sufficient time develop meaningful collaborations responsive projects.  Details the planned FOA provided below. Research Initiative Details facilitate drug discovery development the neuroscience community, NIH Blueprint Neuroscience Research http://neuroscienceblueprint.nih.gov/) established Blueprint Neurotherapeutics Network BPN), collection contract service providers consultants extensive industry experience the areas pharmacology, medicinal chemistry, pharmacokinetics, toxicology, GMP synthesis, formulation development, Phase clinical safety testing. list consultants contract service providers be viewed http://neuroscienceblueprint.nih.gov/bpdrugs/bpn.htm. planned Funding Opportunity Announcement FOA) solicit applications SBIR-eligible small businesses seeking funding through fast-track phased U44 cooperative agreement mechanism help advance drug discovery development projects the clinic.  Applicants be encouraged build customized utilization BPN services their applications. be eligible the BPN, applicant must well-validated bioactive compound(s) hand; BPN does support screening hit compounds. Projects enter BPN during Discovery Development may seek support through phase I/first-in-human testing. Discovery involves iterative medicinal chemistry improve potency ADMET properties compounds, toward goal identifying clinical candidate. During Development, clinical candidate undergoes preclinical toxicology testing required an IND manufacturing, ultimately advancing phase I/first-in-human testing. BPN Development activities include chemical manufacturing controls CMC), formulation development, toxicology studies, regulatory support, phase I/first-in-human testing. NIH assemble customized Lead Development Team each project accepted the program. Lead Development Team typically be co-chaired the Program Director/Principal Investigator PD/PI) a consultant extensive industry expertise identified supported the NIH. Lead Development Team also include members the PD/PI's team, NIH-hired consultants additional expertise, NIH staff. Lead Development Team plan coordinate work supported the cooperative agreement award conducted BPN contractors. projects enter BPN begin a preparatory phase up one year, can used complete any studies required meet Discovery Development entry criteria to engage Lead Development Team establishing detailed research plan, go/no-go milestones, all subsequent work. Applicants strongly encouraged consult NIH program staff plans an application being developed. Consultations include conference calls NIH program staff. Early contact provides opportunity NIH program staff discuss program scope, entry criteria, goals, to provide information guidance how develop competitive application. It's recommended applicants contact NIH staff least 8 weeks before receipt date. additional information the BPN, please http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: Rebecca Farkas, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779 Email: farkasr@ninds.nih.gov nbsp;

Request Information RFI): Neurological Disorders Biorepository Needs, Practices Sources Notice Number: NOT-NS-14-023 Key Dates Release Date: April 3, 2014 Response Date: 23, 2014 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS) committed reducing burden neurological disorders human lives. is time sensitive Request Information RFI) issued the NINDS. purpose the RFI to solicit information biorepository resource needs, practices sources the neuroscience research community. responses the RFI be collected evaluated Institute staff assess best meet current future biorepository resource needs fall within mission the NINDS. Background mission the NINDS Repository, also known the NINDS Human Genetics DNA Cell Line Repository, to accelerate discovery causes, risks mechanisms neurological disease sharing samples data. NINDS Repository, founded 2002 cited almost 300 publications, samples clinical data 45,000 subjects, more 32,000 these presently available researchers academia industry. Samples include genomic DNA de-identified clinical data individuals dystonia, epilepsy, motor neuron disease including ALS), Parkinson’s disease, stroke, Tourette syndrome, neurologically normal controls. NINDS Repository also includes resources sharing fibroblasts, induced pluripotent stem cells, biomarker discovery samples. http://ccr.coriell.org/Sections/Collections/NINDS/?SsId=10 detailed information regarding NINDS Repository collections, clinical data forms, de-identified clinical data, publications citing resource, policies. Information Requested NINDS seeks information the following areas: 1. Sources business practices. NINDS requests information regarding biorepository business practices. particular NINDS seeks identify sources to gather information regarding repository business practices for, not limited to, biomarkers collections. Comments also include information regarding sample types, timeline throughput capabilities, storage capacity, infrastructure management, including interfacing large external databases, distribution infrastructure, repository project management strategy practices, cost/pricing structure practices. NINDS Repository biomarkers collections presently include: Parkinson's Disease Biomarkers Program, https://pdbp.ninds.nih.gov/jsp/how-pdbp-works.jsp), BioFIND http://ccr.coriell.org/Sections/Collections/NINDS/BioFIND.aspx?coll=ND&…), Predict-HD http://ccr.coriell.org/Sections/Collections/NINDS/BioFIND.aspx?coll=ND&…), emerging collections frontotemporal dementia traumatic brain injury. 2. Repository science innovation. NINDS Repository presently includes DNA limited de-identified clinical data virtually samples accepted, and, a subset, includes: cryopreserved lymphocytes, lymphoblastoid cell lines, fibroblasts, induced pluripotent stem cells, cerebrospinal fluid, plasma, RNA, serum. NINDS seeks information regarding innovative approaches repository science, example, regarding sample types, IT, business practices, consider planning future the resource. 3. Best practices. NINDS Repository contributed a number protocols sample handing, preparation, shipping, including, example, PDBP biomarkers Laboratory Manual https://pdbp.ninds.nih.gov/assets/policy/PDBP%20Research%20Biomarkers%2…), the NINDS Repository Submitter's Guide http://ccr.coriell.org/PDF/NINDS/submitter_guide.pdf). NINDS seeks information regarding additional authoritative best practices can further inform future NINDS Repository activities. to Submit Responses Responses must submitted electronically using web-based form www.ninds.nih.gov/funding/RFI-Biorepository.htm will accepted through 23, 2014. Replies individual questions optional, the site permit anonymous responses.   information provided be kept confidential, will used assist NINDS its strategic planning efforts only. NINDS not provide comments any responder’s submission. However, responses the RFI inform future funding opportunity announcements. Respondents further advised the Government under obligation acknowledge receipt the information received provide feedback respondents respect any information submitted. proprietary, classified, confidential, sensitive information should included your response. Government reserves right use any non-proprietary technical information any resultant solicitation(s). request for information planning purposes only should be construed a solicitation as obligation the part the Federal Government. NIH does intend make any awards based responses this RFI to otherwise pay the preparation any information submitted for Government's of such information. Inquiries Please direct inquiries to: Roderick A. Corriveau, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-5680 Email: roderick.corriveau@nih.gov nbsp;

Notice Modification the Data Sharing Policy the Federal Interagency Traumatic Brain Injury Research FITBIR) Informatics System Notice Number: NOT-NS-14-022 Key Dates Release Date: March 27, 2014 Related Announcements NOT-NS-17-029 NOT-NS-12-016 NOT-NS-12-017 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Data Sharing Policy the Federal Interagency Traumatic Brain Injury Research FITBIR) Informatics System modified accelerate access data to promote collaboration.  modifications below. FITBIR Data Sharing Schedule Six months after submission the data, the Core (required) and Basic recommended) TBI common data elements CDEs) are used the study are expected be available all qualified approved researchers Recipients) determined the Data Access Quality Committee DAQC).  data fields also made available the submitting program director/principal investigator’s PD/PI's), i.e. Submitter’s, discretion.   Outcomes data other data elements needed the PD/PI test his/her hypotheses research questions, referred as Experimental Data, be available a staged manner.  Six months after award period ends, Experimental Data be open other researchers have submitted data FITBIR Submitters). Twelve months after award period ends, Experimental Data be open all qualified approved researchers Recipients).   Table.  Summary the FITBIR Data Sharing Schedule Core Basic CDEs Data uploaded quarterly after subject enrollment begins data available six months after submission all approved FITBIR Data Recipients. Specific CDEs be exempted pending approval the DAQC they needed test primary study hypothesis research question. Experimental Data approved FITBIR Data Recipients gain access either: Six months after award period ends they a FITBIR Submitter; or  Twelve months after award period ends those are FITBIR Submitters. Access also granted earlier agreed by Submitters ongoing study(s) in rare cases the DAQC over rules Submitters’ denial the grounds the request does compromise completion the ongoing study. Investigators also strongly encouraged collaborate share data throughout study accelerate research advance knowledge TBI.  facilitate collaboration, data access request forms be submitted before award period ends the DAQC initial review then forwarded to relevant Submitters.  Submitters choose collaborate and/or provide access all some their Experimental Data, which case data be available the data Recipients.  Alternatively, Submitters choose deny early access, which case request be reviewed the DAQC in consultation with Submitters.  this case, approvals early access only granted the DACQ it clear the data request does negatively impact completion the original study. example, prospective data collection projects are powered answer specific questions be jeopardized premature analysis these same questions. However, important research be accomplished without jeopardizing study, value the FITBIR data be greatly enhanced data sharing advances science TBI. Inquiries Please direct inquiries to: FITBIR Operations Team Email: FITBIR-ops@mail.nih.gov Website: https://fitbir.nih.gov/  

Discontinuation PAR-13-127 NINDS Ruth L. Kirschstein National Research Service Awards Individual Predoctoral Fellows MD-PhD Programs F31)" Notice Number: NOT-NS-14-018 Key Dates Release Date: March 14, 2014 Related Announcements PAR-13-127 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice to inform potential applicants NINDS discontinue PAR-13-127 NINDS Ruth L. Kirschstein National Research Service Awards Individual Predoctoral Fellows MD-PhD Programs F31)".   New applications be accepted NINDS this Funding Opportunity Announcement FOA) through April 8, 2014, due date 7, 2014, AIDS AIDS-related applications).  order accommodate applicants need revise resubmit fellowship applications, NINDS accept resubmission applications A1) through December 8, 2014, due date January 7, 2015, AIDS AIDS-related applications). Starting the April 8, 2014, fellowship application due date, applicants submit F30 applications NINDS support dual-degree training using Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral MD/PhD Other Dual-Doctoral Degree Fellowship Parent F30). Inquiries Please direct inquiries to: Stephen Korn, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-4188 Email: Korns@ninds.nih.gov  

Notice Clarify Intellectual Property Requirements PAR-11-344 NeuroNEXT Infrastructure Resource Access X01)" Notice Number: NOT-NS-14-019 Key Dates Release Date: March 13, 2014 Related Announcements PAR-11-344 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice modifies language NINDS PAR-11-344 quot;NeuroNEXT Infrastructure Resource Access X01)" regarding intellectual property requirements. Part 2. Section I. Funding Opportunity Description Purpose Currently reads: Applicants should note the following: 1) applicant must hold intellectual property rights IP) the investigational agent/device proposed study. Modified read: Applicants should note the following: 1) applicants industry must hold intellectual property IP) rights the investigational agent/device proposed study. However, applicants non-profits not need hold IP rights the investigational agent/device under study. other aspects the FOA remain unchanged. Inquiries Please direct inquiries to: Amanda Sibley, DPhil, MPH National Institute Neurological Disorders Stroke NINDS) Telephone: 301-451-1449 Email: amanda.sibley@nih.gov nbsp;